Skip to main navigation Skip to search Skip to main content

Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies

  • Harjeet Singh
  • , Matthew J. Figliola
  • , Margaret J. Dawson
  • , Helen Huls
  • , Simon Olivares
  • , Kirsten Switzer
  • , Tiejuan Mi
  • , Sourindra Maiti
  • , Partow Kebriaei
  • , Dean A. Lee
  • , Richard E. Champlin
  • , Laurence J.N. Cooper

Research output: Contribution to journal › Article › peer-review

Abstract

Improving the therapeutic efficacy of T cells expressing a chimeric antigen receptor (CAR) represents an important goal in efforts to control B-cell malignancies. Recently an intrinsic strategy has been developed to modify the CAR itself to improve T-cell signaling. Here we report a second extrinsic approach based on altering the culture milieu to numerically expand CAR + T cells with a desired phenotype, for the addition of interleukin (IL)-21 to tissue culture improves CAR-dependent T-cell effector functions. We used electrotransfer of Sleeping Beauty system to introduce a CAR transposon and selectively propagate CAR+ T cells on CD19+ artificial antigen-presenting cells (aAPC). When IL-21 was present, there was preferential numeric expansion of CD19-specific T cells which lysed and produced IFN-γ in response to CD19. Populations of these numerically expanded CAR+ T cells displayed an early memory surface phenotype characterized as CD62L +CD28+ and a transcriptional profile of naïve T cells. In contrast, T cells propagated with only exogenous IL-2 tended to result in an overgrowth of CD19-specific CD4+ T cells. Furthermore, adoptive transfer of CAR+ T cells cultured with IL-21 exhibited improved control of CD19+ B-cell malignancy in mice. To provide coordinated signaling to propagate CAR+ T cells, we developed a novel mutein of IL-21 bound to the cell surface of aAPC that replaced the need for soluble IL-21. Our findings show that IL-21 can provide an extrinsic reprogramming signal to generate desired CAR+ T cells for effective immunotherapy.

Original languageEnglish
Pages (from-to)3516-3527
Number of pages12
JournalCancer Research
Volume71
Issue number10
DOIs
StatePublished - May 15 2011

Fingerprint

Dive into the research topics of 'Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies'. Together they form a unique fingerprint.

Cite this